Market Overview:
The global biological product manufacturing market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing demand for monoclonal antibodies, recombinant proteins, growth hormones, beta interferon, and therapeutic enzymes. In addition, the increasing prevalence of chronic diseases is also contributing to the growth of this market. The hospitals segment is expected to dominate the global biological product manufacturing market during the forecast period. This segment is expected to grow at a CAGR of 11% from 2018 to 2030. The specialized clinics segment is also projected to grow at a high rate during the forecast period owing to rising demand for personalized medicines and growing awareness about advanced therapies among patients.
Product Definition:
Biological product manufacturing is the process of creating biologic products, which are drugs derived from living organisms. These products can be used to treat a variety of medical conditions, and the importance of biological product manufacturing cannot be overstated. Biologic drugs have revolutionized modern medicine, and many patients now rely on them to stay healthy or to treat life-threatening illnesses.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules, which are manufactured by the human body. There is a wide range of monoclonal antibodies available in the market with different applications and uses. Some of them include therapeutic and diagnostic agents used for treating cancer, arthritis, etc., while others find application in research settings to isolate or identify an antigenic target molecule for study purposes.
Recombinant Proteins:
Recombinant proteins are the protein products manufactured by the genetic engineering technology. The recombinant proteins have various applications in biotechnology and pharmaceutical industries. Recombinant Proteins market is segmented on the basis of application into Diagnostics & Therapeutics (D&T). Diagnostic and therapeutics segments are further sub-segmented into Cancer, Cardiovascular Diseases (CVD), Blood Disorders, Autoimmune Diseases, Infectious diseases & others.
Application Insights:
The hospitals application segment dominated the global market in 2017. This can be attributed to factors such as increasing healthcare spending, growing geriatric population, and technological advancements that have facilitated easy access to patients¢â‚¬â„¢ records. Hospitals are majorly involved in the production of biologics like recombinant proteins, monoclonal antibodies (mAb), growth hormones, and interferons.
Specialized clinics are anticipated to register a higher CAGR over the forecast period owing to factors such as an increase in demand for minimally invasive surgeries coupled with rising incidences of chronic diseases requiring longterm medication.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturers and increased focus on drug development is expected to drive the regional market over the forecast period. In addition, increasing government funding for R&D activities in this sector is also expected to propel growth during the same period.
Asia Pacific region accounted for a revenue share of 23% in 2017 owing to an increase in investments by leading biopharmaceutical companies and growing awareness about new treatment options among patients are some factors driving growth.
Growth Factors:
- Increasing demand for biologics from the pharmaceutical and biotechnology industries
- Growing prevalence of chronic diseases that require treatment with biologics
- Rising public and private investments in research and development of new therapies based on biological products
- Advances in manufacturing technologies for producing large quantities of high-quality biologic drugs
- Emergence of novel delivery platforms for administering therapeutic proteins and peptides
Scope Of The Report
Report Attributes
Report Details
Report Title
Biological Product Manufacturing Market Research Report
By Type
Monoclonal Antibodies, Recombinant Proteins, Growth Hormones, Beta Interferon, Therapeutic Enzymes
By Application
Hospitals, Specialized Clinics, Government Research Institutes
By Companies
Novartis, F.Hoffmann-La Roche, Merck, Bayer, Lonza, China Biologic Products, Pfizer, Sanofi, Teva Pharmaceutical Industries, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
186
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Biological Product Manufacturing Market Report Segments:
The global Biological Product Manufacturing market is segmented on the basis of:
Types
Monoclonal Antibodies, Recombinant Proteins, Growth Hormones, Beta Interferon, Therapeutic Enzymes
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialized Clinics, Government Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- F.Hoffmann-La Roche
- Merck
- Bayer
- Lonza
- China Biologic Products
- Pfizer
- Sanofi
- Teva Pharmaceutical Industries
- Amgen
Highlights of The Biological Product Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Recombinant Proteins
- Growth Hormones
- Beta Interferon
- Therapeutic Enzymes
- By Application:
- Hospitals
- Specialized Clinics
- Government Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biological Product Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biological product manufacturing is the process of creating a biological product, such as a vaccine or drug. This process begins with research and development (R&D), which involves developing new products using scientific methods. After R&D, the products are tested in animal trials to determine if they are safe and effective. If they meet these standards, they are then submitted to regulatory agencies for approval. Once approved, manufacturers produce the products using various techniques, including biotechnology and chemical synthesis.
Some of the major players in the biological product manufacturing market are Novartis, F.Hoffmann-La Roche, Merck, Bayer, Lonza, China Biologic Products, Pfizer, Sanofi, Teva Pharmaceutical Industries, Amgen.
The biological product manufacturing market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biological Product Manufacturing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biological Product Manufacturing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biological Product Manufacturing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biological Product Manufacturing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biological Product Manufacturing Market Size & Forecast, 2018-2028
4.5.1 Biological Product Manufacturing Market Size and Y-o-Y Growth
4.5.2 Biological Product Manufacturing Market Absolute $ Opportunity
Chapter 5 Global Biological Product Manufacturing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Biological Product Manufacturing Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Recombinant Proteins
5.2.3 Growth Hormones
5.2.4 Beta Interferon
5.2.5 Therapeutic Enzymes
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Biological Product Manufacturing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Biological Product Manufacturing Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialized Clinics
6.2.3 Government Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biological Product Manufacturing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biological Product Manufacturing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Biological Product Manufacturing Analysis and Forecast
9.1 Introduction
9.2 North America Biological Product Manufacturing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Biological Product Manufacturing Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Recombinant Proteins
9.6.3 Growth Hormones
9.6.4 Beta Interferon
9.6.5 Therapeutic Enzymes
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Biological Product Manufacturing Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialized Clinics
9.10.3 Government Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Biological Product Manufacturing Analysis and Forecast
10.1 Introduction
10.2 Europe Biological Product Manufacturing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Biological Product Manufacturing Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Recombinant Proteins
10.6.3 Growth Hormones
10.6.4 Beta Interferon
10.6.5 Therapeutic Enzymes
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Biological Product Manufacturing Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialized Clinics
10.10.3 Government Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Biological Product Manufacturing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Biological Product Manufacturing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Biological Product Manufacturing Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Recombinant Proteins
11.6.3 Growth Hormones
11.6.4 Beta Interferon
11.6.5 Therapeutic Enzymes
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Biological Product Manufacturing Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialized Clinics
11.10.3 Government Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Biological Product Manufacturing Analysis and Forecast
12.1 Introduction
12.2 Latin America Biological Product Manufacturing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Biological Product Manufacturing Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Recombinant Proteins
12.6.3 Growth Hormones
12.6.4 Beta Interferon
12.6.5 Therapeutic Enzymes
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Biological Product Manufacturing Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialized Clinics
12.10.3 Government Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Biological Product Manufacturing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Biological Product Manufacturing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Biological Product Manufacturing Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Recombinant Proteins
13.6.3 Growth Hormones
13.6.4 Beta Interferon
13.6.5 Therapeutic Enzymes
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Biological Product Manufacturing Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialized Clinics
13.10.3 Government Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biological Product Manufacturing Market: Competitive Dashboard
14.2 Global Biological Product Manufacturing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 F.Hoffmann-La Roche
14.3.3 Merck
14.3.4 Bayer
14.3.5 Lonza
14.3.6 China Biologic Products
14.3.7 Pfizer
14.3.8 Sanofi
14.3.9 Teva Pharmaceutical Industries
14.3.10 Amgen
